Clinical Trials Logo

Postural Tachycardia Syndrome clinical trials

View clinical trials related to Postural Tachycardia Syndrome.

Filter by:

NCT ID: NCT04050410 Recruiting - Clinical trials for Postural Tachycardia Syndrome

Autonomic Determinants of POTS - Pilot1

Start date: August 27, 2019
Phase: Early Phase 1
Study type: Interventional

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing. Many of these patients are disabled and have a poor quality of life. The sympathetic nerves are part of the nervous system that helps to maintain normal blood pressures and heart rates during activities of daily life. The purpose of this study is to determine the importance of sympathetic activation as a cause of orthostatic symptoms. The investigators will assess the effects of a blood pressure medication (Moxonidine) on the symptoms during standing. Moxonidine lowers sympathetic activity. The investigators believe patients with high resting sympathetic activity might benefit from Moxonidine. It might reduce high heart rate and improve symptoms during standing. This study should help clinicians and the growing population of patients with POTS gain a better understanding of this disorder and find more personalized treatment.

NCT ID: NCT02673996 Recruiting - Clinical trials for Postural Tachycardia Syndrome

POTS Adrenergic Ab (CIHR Aims #1&2)

Start date: January 2016
Phase:
Study type: Observational

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

NCT ID: NCT00409435 Recruiting - Clinical trials for Postural Tachycardia Syndrome

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Start date: October 2006
Phase: Phase 2
Study type: Interventional

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.